The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1930-1940

  Loregian, Arianna ^a   Mercorelli, Beatrice ^a   Muratore, Giulia ^a   Sinigalia, Elisa ^a   Pagni, Silvana ^a   Massari, Serena ^b   Gribaudo, Giorgio ^c   Gatto, Barbara ^a   Palumbo, Manlio ^a   Tabarrini, Oriana ^b   Cecchetti, Violetta ^b   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOQUINOLONE; DNA POLYMERASE; GANCICLOVIR; IMMEDIATE EARLY 2 PROTEIN; MESSENGER RNA; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; WC 5;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INFECTION; INOCULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA TRANSLATION; STRUCTURE ACTIVITY RELATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AMINOQUINOLINES; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG SYNERGISM; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMEDIATE-EARLY PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 77951226066     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01730-09     Document Type: Article

References (42)

1. Andrei, G., E. De Clercq, and R. Snoeck. 2008. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9:132-145.
2. Andriole, V. T. 1988. The quinolones. Academic Press, London, United Kingdom.
3. Asmar, J., L. Wiebusch, M. Truss, and C. Hagemeier. 2004. The putative zinc finger of the human cytomegalovirus IE2 86-kilodalton protein is dispensable for DNA binding and autorepression, thereby demarcating a concise core domain in the C terminus of the protein. J. Virol. 78:11853-11864.
4. Azad, R. F., V. B. Driver, K. Tanaka, R. M. Crooke, and K. P. Anderson. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37:1945-1954.
5. Biron, K. K., J. A. Fyfe, S. C. Stanat, L. K. Leslie, J. B. Sorrell, C. U. Lambe, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. U. S. A. 83:8769-8773.
6. Boulware, S. L., J. C. Bronstein, E. C. Nordby, and P. C. Weber. 2001. Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res. 51:111-125.
7. Brideau, R. J., M. L. Knechtel, A. Huang, V. A. Vaillancourt, E. E. Vera, N. L. Oien, T. A. Hopkins, J. L. Wieber, K. F. Wilkinson, B. D. Rush, F. J. Schwende, and M. W. Wathen. 2002. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. 54:19-28.
8. Britt, W. 2008. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325:417-470.
9. Cecchetti, V., C. Parolin, S. Moro, T. Pecere, E. Filipponi, A. Calistri, O. Tabarrini, B. Gatto, M. Palumbo, A. Fravolini, and G. Palu. 2000. 6-Aminoquinolones as new potential anti-HIV agents. J. Med. Chem. 43:3799-3802.
10. Coen, D. M., and P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2:278-288.
11. De Bolle, L., G. Andrei, R. Snoeck, Y. Zhang, A. Van Lommel, M. Otto, A. Bousseau, C. Roy, E. De Clercq, and L. Naesens. 2004. Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem. Pharmacol. 67:325-336.
12. Elion, G. B., S. Singer, and G. H. Hitchings. 1954. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
13. Evers, D. L., G. Komazin, R. G. Ptak, D. Shin, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2004. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48:3918-3927.
14. Huang, L., Y. Zhu, and D. G. Anders. 1996. The variable 3′ ends of a human cytomegalovirus oriLyt transcript (SRT) overlap an essential, conserved replicator element. J. Virol. 70:5272-5281.
15. Jacobson, J. G., T. E. Renau, M. R. Nassiri, D. G. Sweier, J. M. Breitenbach, L. B. Townsend, and J. C. Drach. 1999. Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrob. Agents Chemother. 43:1888-1894.
16. Kari, B., and R. Gehrz. 1992. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J. Virol. 66:1761-1764.
17. Lewis, A. F., J. C. Drach, S. M. Fennewald, J. H. Huffman, R. G. Ptak, J. P. Sommadossi, G. R. Revankar, and R. F. Rando. 1994. Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system. Antimicrob. Agents Chemother. 38:2889-2895.
18. Loregian, A., and D. M. Coen. 2006. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol. 13:191-200.
19. Loregian, A., R. Rigatti, M. Murphy, E. Schievano, G. Palu, and H. S. Marsden. 2003. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit. J. Virol. 77:8336-8344.
20. Loregian, A., E. Sinigalia, B. Mercorelli, G. Palù, and D. M. Coen. 2007. Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanism. Nucleic Acids Res. 35:4779-4791.
21. Luganini, A., P. Caposio, S. Landolfo, and G. Gribaudo. 2008. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob. Agents Chemother. 52:1111-1120.
22. Luganini, A., P. Caposio, M. Mondini, S. Landolfo, and G. Gribaudo. 2008. New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. 105:1791-1801.
23. Meier, J. L., and M. F. Stinski. 2006. Major immediate-early enhancer and its gene products, p. 151-166. In M. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, United Kingdom.
24. Mengoli, C., R. Cusinato, M. A. Biasolo, S. Cesaro, C. Parolin, and G. Palù. 2004. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J. Med. Virol. 74:78-84.
25. Mercorelli, B., G. Muratore, E. Sinigalia, O. Tabarrini, M. A. Biasolo, V. Cecchetti, G. Palù, and A. Loregian. 2009. A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity. Antimicrob. Agents Chemother. 53:312-315.
26. Mercorelli, B., E. Sinigalia, A. Loregian, and G. Palù. 2008. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol. 18:177-210.
27. Mocarski, E. S., T. Shenk, and R. F. Pass. 2007. Cytomegaloviruses, p. 2701-2772. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
28. Oien, N. L., R. J. Brideau, T. A. Hopkins, J. L. Wieber, M. L. Knechtel, J. A. Shelly, R. A. Anstadt, P. A. Wells, R. A. Poorman, A. Huang, V. A. Vaillancourt, T. L. Clayton, J. A. Tucker, and M. W. Wathen. 2002. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. 46:724-730.
29. Pari, G. S., and D. G. Anders. 1993. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J. Virol. 67:6979-6988.
30. Richter, S., C. Parolin, B. Gatto, C. Del Vecchio, E. Brocca-Cofano, A. Fravolini, G. Palù, and M. Palumbo. 2004. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. 48:1895-1899.
31. Richter, S., C. Parolin, M. Palumbo, and G. Palù. 2004. Antiviral properties of quinolone-based drugs. Curr. Drug Targets Infect. Disord. 4:111-116.
32. Sanchez, V., and D. H. Spector. 2006. Exploitation of host cell cycle regulatory pathways by HCMV, p. 205-230. In M. Reddehase (ed.), Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, United Kingdom.
33. Scholz, M., H. W. Doerr, and J. Cinatl. 2001. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res. 49:129-145.
34. Schwartz, R., M. H. Sommer, A. Scully, and D. H. Spector. 1994. Site-specific binding of the human cytomegalovirus IE2 86-kilodalton protein to an early gene promoter. J. Virol. 68:5613-5622.
35. Shogan, B., L. Kruse, G. B. Mulamba, A. Hu, and D. M. Coen. 2006. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80:4740-4747.
36. Snoeck, R., G. Andrei, B. Bodaghi, L. Lagneaux, D. Daelemans, E. de Clercq, J. Neyts, D. Schols, L. Naesens, S. Michelson, D. Bron, M. J. Otto, A. Bousseau, C. Nemecek, and C. Roy. 2002. 2-Chloro-3-pyridin-3-yl-5,6,7,8- tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res. 55:413-424.
37. Stevens, M., J. Balzarini, O. Tabarrini, G. Andrei, R. Snoeck, V. Cecchetti, A. Fravolini, E. De Clercq, and C. Pannecouque. 2005. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J. Antimicrob. Chemother. 56:847-855.
38. Stinski, M. F. 1978. Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. J. Virol. 26:686-701.
39. Tabarrini, O., S. Massari, D. Daelemans, M. Stevens, G. Manfroni, S. Sabatini, J. Balzarini, V. Cecchetti, C. Pannecouque, and A. Fravolini. 2008. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J. Med. Chem. 51:5454-5458.
40. Tabarrini, O., M. Stevens, V. Cecchetti, S. Sabatini, M. Dell'Uomo, G. Manfroni, M. Palumbo, C. Pannecouque, E. De Clercq, and A. Fravolini. 2004. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J. Med. Chem. 47:5567-5578.
41. Villarreal, E. C. 2003. Current and potential therapies for the treatment of herpes-virus infections. Prog. Drug Res. 60:263-307.
42. Wu, J., J. O'Neill, and M. S. Barbosa. 1998. Transcription factor Sp1 mediates cell-specific trans-activation of the human cytomegalovirus DNA polymerase gene promoter by immediate-early protein IE86 in glioblastoma U373MG cells. J. Virol. 72:236-244.